Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [(177)Lu]Lu-PSMA-617

Genitourinary Cancer

Final overall survival and safety analyses of the phase 3 PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

Ann Oncol

Fizazi K, Chi KN, Shore ND, Herrmann K, de Bono JS, Castellano D, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Fleming M, Haas T, Ghebremariam S, Kreisl TN, Rajagopalan S, Sartor O, Morris MJ, PSMAfore Investigators

doi: 10.1016/j.annonc.2025.07.003

CHICAGO 2025

Genitourinary Cancer

PSMA-delay castration: ¹⁷⁷Lu-PSMA-617 versus observation in patients with PSMA-positive oligometastatic prostate cancer

Genitourinary Cancer

Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience

Prostate

Losee M, Kavanaugh M, Liu M, Borges N, Haberman V, Ritzer J, Wolanski A, Bhimaniya S, Choudhury AD, Hyun H, Stoltenberg H, Kilbridge KL, Morgans A, Pomerantz M, Robertson M, Sakellis C, Shah H, Taplin ME, Wei XX, Ng T, Ravi P, Jacene H

doi: 10.1002/pros.24880

Genitourinary Cancer

(177)Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study

Eur J Cancer

Mandel P, Groener D, Follacchio G, Ürün Y, Bourlon MT, Sabet A, Grünwald F, Tural D, Büttner T, Kopp RM, Taha T, Chun FK, Facchini G, Myint ZW, Seront E, Conteduca V, Quiroga MNG, Aurilio G, Palacios GA, Bögemann M, Roviello G, Matrana MR, Sammarco E, Laguado MIZ, Galli L, Ansari J, Danielli L, Molina-Cerrillo J, Rescigno P, Yazgan SC, Bastos DA, Jazieh AR, Monteiro FSM, Soares A, Massari F, Wenzel M, Capoccetti F, Santoni M

doi: 10.1016/j.ejca.2025.115789

Genitourinary Cancer

Time to Castration Resistance is Associated With Overall Survival Even After the Achievement of Castration Resistance in Metastatic Prostate Cancer

Prostate

Kato H, Goto Y, Kojima S, Onoda Y, Wakai K, Hou K, Araki K, Sakamoto S, Ichikawa T, Naya Y

doi: 10.1002/pros.24850

Breast Cancer

Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer

Ann Oncol

Mamann A, Pradat Y, Bidard FC, Delaloge S, Cabel L, Faull I, Marques S, Bachelot T, Dalenc F, DE LA Motte Rouge T, Pistilli B, Samaniego J, Frenel JS, Levy C, Ferrero JM, Sabatier R, Ladoire S, Chakiba C, Hardy AC, Lemonnier J, Mahi Y, Andre F, Cournede PH, Michiels S, Bernard E

doi: 10.1016/j.annonc.2025.06.015

CHICAGO 2025

Genitourinary Cancer

Earlier initiation of ¹⁷⁷Lu-PSMA-617 is associated with improved clinical outcomes in patients with mCRPC in a real-world setting

COMMENTED

Genitourinary Cancer

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update

★ 1 Recommended and commented by Prof. Dr Richard Cathomas, Faculty Member

J Clin Oncol

Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM, Herchenhorn D, Zhang T, Beckermann KE, Vapiwala N, Carducci MA, Celano P, Hotte SJ, Basu A, Borno H, Bryce AH, Wang P, Wulff-Burchfield E, Bodei L, Loblaw A, Hamilton RJ, Emamekhoo H, Hope TA, He H, Murad MH, Liu H, Williams JE Jr, Parikh RA

doi: 10.1200/JCO-25-00007

Gastrointestinal Cancer

Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis

Cancer Treat Rev

Holz A, Paul B, Zapf A, Pantel K, Joosse SA

doi: 10.1016/j.ctrv.2025.102999

Related content

Final overall survival and safety analyses of the phase 3 PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

PSMA-delay castration: 177Lu-PSMA-617 versus observation in patients with PSMA-positive oligometastatic prostate cancer

Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience

(177)Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study

Time to Castration Resistance is Associated With Overall Survival Even After the Achievement of Castration Resistance in Metastatic Prostate Cancer

Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer

Earlier initiation of 177Lu-PSMA-617 is associated with improved clinical outcomes in patients with mCRPC in a real-world setting

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update

Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis

PSMA-delay castration: ¹⁷⁷Lu-PSMA-617 versus observation in patients with PSMA-positive oligometastatic prostate cancer

Earlier initiation of ¹⁷⁷Lu-PSMA-617 is associated with improved clinical outcomes in patients with mCRPC in a real-world setting